XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $13,663 | $5,504 | $6,596 | $14,736 |
| - Cash | $371 | $1,401 | $2,094 | $2,969 |
| + Debt | $138 | $0 | $0 | $0 |
| Enterprise Value | $13,430 | $4,103 | $4,502 | $11,767 |
| Revenue | $451 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $3 | $0 | -$1 | -$1 |
| % Margin | 0.7% | – | – | – |
| EBITDA | -$930 | -$764 | -$879 | -$1,030 |
| % Margin | -206.2% | – | – | – |
| Net Income | -$1,027 | -$2 | -$1,348 | $435 |
| % Margin | -227.7% | – | – | – |
| EPS Diluted | -0.15 | 0 | -0.25 | 0.07 |
| % Growth | – | 100% | -457.1% | – |
| Operating Cash Flow | -$1,618 | -$707 | -$901 | -$1,049 |
| Capital Expenditures | -$54 | $0 | $0 | $0 |
| Free Cash Flow | -$1,672 | -$707 | -$901 | -$1,049 |